PT - JOURNAL ARTICLE AU - MASATSUNE SHIBUTANI AU - HISASHI NAGAHARA AU - TATSUNARI FUKUOKA AU - YASUHITO ISEKI AU - EN WANG AU - YUKI OKAZAKI AU - SHINICHIRO KASHIWAGI AU - KIYOSHI MAEDA AU - KOSEI HIRAKAWA AU - MASAICHI OHIRA TI - Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer AID - 10.21873/anticanres.14415 DP - 2020 Jul 01 TA - Anticancer Research PG - 4157--4163 VI - 40 IP - 7 4099 - http://ar.iiarjournals.org/content/40/7/4157.short 4100 - http://ar.iiarjournals.org/content/40/7/4157.full SO - Anticancer Res2020 Jul 01; 40 AB - Background/Aim: The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated. However, little is known about the impact of a usage history of bevacizumab in front-line treatment on the clinical benefit of combining bevacizumab with FTD/TPI. Patients and Methods: A total of 62 patients with mCRC treated with FTD/TPIĀ±bevacizumab was enrolled and assessed for chemotherapeutic efficacy and adverse events. Results: Regardless of the usage history of bevacizumab in front-line treatment, the FTD/TPI plus bevacizumab group had a significantly better progression-free survival rate than the FTD/TPI monotherapy group, and no significant differences in the safety profile were observed between the two groups. Conclusion: Combining bevacizumab with FTD/TPI improves the survival outcomes with manageable toxicity, regardless of the usage history of bevacizumab in front-line treatment, in patients with mCRC.